Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Mar 5:6:25.
doi: 10.1186/1742-4690-6-25.

Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors

Erik Serrao  1 , Srinivas Odde, Kavya Ramkumar, Nouri Neamati
Affiliations
Review

Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors

Erik Serrao et al. Retrovirology. .

Erratum in

  • Retrovirology. 2009;6:33

Abstract

Merck's MK-0518, known as raltegravir, has recently become the first FDA-approved HIV-1 integrase (IN) inhibitor and has since risen to blockbuster drug status. Much research has in turn been conducted over the last few years aimed at recreating but optimizing the compound's interactions with the protein. Resulting me-too drugs have shown favorable pharmacokinetic properties and appear drug-like but, as expected, most have a highly similar interaction with IN to that of raltegravir. We propose that, based upon conclusions drawn from our docking studies illustrated herein, most of these me-too MK-0518 analogues may experience a low success rate against raltegravir-resistant HIV strains. As HIV has a very high mutational competence, the development of drugs with new mechanisms of inhibitory action and/or new active substituents may be a more successful route to take in the development of second- and third-generation IN inhibitors.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The structure of diketo acid-based HIV-1 integrase inhibitors.
Figure 2
Figure 2
Requirements for "second generation drug" classification.
Figure 3
Figure 3
The evolution of dihydroxypyrimidine-4-carboxamides.
Figure 4
Figure 4
The evolution of N-methylpyrimidones.
Figure 5
Figure 5
Dihydroxypyrido-pyrazine-1,6-dione representative example.
Figure 6
Figure 6
The evolution of bicyclic pyrimidones.
Figure 7
Figure 7
The evolution of pyrrolloquinolones.
Figure 8
Figure 8
Docking poses of selected HIV-1 integrase inhibitors upon the 1BL3 IN crystal structure. A, MK-0518; B, S-1360; C, L870,810; D, GSK-364735; E, GS-9137; F, compound 2; G, compound 11; H, compound 16; I, compound 17; J, compound 26.
See this image and copyright information in PMC

References

    1. UNAIDS AIDS epidemic update. 2007. http://data.unaids.org/pub/EPISlides/2007/2007_epiupdate_en.pdf
    1. The Henry J Kaiser Family Foundation The global HIV/AIDS epidemic. HIV/AIDS Policy Fact Sheet. 2007. http://www.kff.org/hivaids/upload/3030-103.pdf
    1. Klimas N, Koneru AO, Fletcher MA. Overview of HIV. Psychosom Med. 1984;70:523–530. - PubMed
    1. Centers for Disease Control and Prevention Using the BED HIV-1 capture EIA assay to estimate incidence using STARHS in the context of surveillance in the United States. 2006. http://data.unaids.org/pub/EPISlides/2006/Statement_BED_Policy_13Dec05_e...
    1. Hammer SM, Eron JJ, Jr, Reiss P, Schooley RT, Thompson MA, Walmsley S, Cahn P, Fischl MA, Gatell JM, Hirsch MS, Jacobsen DM, Montaner JS, Richman DD, Yeni PG, Volberding PA. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society USA panel. JAMA. 2008;300:555–570. - PubMed

MeSH terms